These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 17511767

  • 1. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
    Steers WD, Herschorn S, Kreder KJ, Moore K, Strohbehn K, Yalcin I, Bump RC, Duloxetine OAB Study Group.
    BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
    [Abstract] [Full Text] [Related]

  • 2. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 3. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW, Rovner ES, Bavendam T.
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [Abstract] [Full Text] [Related]

  • 4. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D, Cardozo L, Terpstra G, Bolodeoku J, Tamsulosin Study Group.
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [Abstract] [Full Text] [Related]

  • 5. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M.
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [Abstract] [Full Text] [Related]

  • 6. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [Abstract] [Full Text] [Related]

  • 7. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG, Al-Buheissi S.
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [Abstract] [Full Text] [Related]

  • 8. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T.
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [Abstract] [Full Text] [Related]

  • 10. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M.
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A, Wyndaele JJ, Sieber P.
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [Abstract] [Full Text] [Related]

  • 13. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J, SUNRISE Study Group.
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [Abstract] [Full Text] [Related]

  • 15. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Japanese Solifenacin Study Group.
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [Abstract] [Full Text] [Related]

  • 16. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD, Lucente V, Vapnek J, Smith N.
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [Abstract] [Full Text] [Related]

  • 17. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
    Bach P, Wormland RT, Möhring C, Goepel M.
    Neurourol Urodyn; 2009 Mar; 28(3):209-13. PubMed ID: 19205067
    [Abstract] [Full Text] [Related]

  • 18. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 19. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z.
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [Abstract] [Full Text] [Related]

  • 20. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training.
    Brunenberg DE, Joore MA, Veraart CP, Berghmans BC, van der Vaart CH, Severens JL.
    Clin Ther; 2006 Apr; 28(4):604-18. PubMed ID: 16750472
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.